Employees 2013: 85,080
Employees 2012: 82,089
% Change: +3.64
Revenues 2013: $52.31 billion
Revenues per employee: $614,797

Although there were some definite hiccups, Roche ($RHHBY) came out of 2013 a happy camper. The company hired nearly 3,000 new employees. While Roche is on the lower end of this list, it had the second highest employee hiring numbers, coming in right after Novartis ($NVS). And even though it added people, its revenue per employee was the second best on the list, behind only Pfizer ($PFE), which got there by cutting people.

The Swiss drugmaker grew thanks to a strong year of sales. Its revenue grew 9.43% in 2013. Cancer drugs Herceptin, Avastin and Xeloda, age-related macular degeneration drug Lucentis and rheumatoid arthritis drug Actemra led the drug sales.

Roche hit some roadblocks, pulling the plug on diabetes drug aleglitazar, once tapped as a blockbuster hopeful. Then its successful R&D chief, Hal Barron, left for a new position at Google ($GOOG). Sandra Horning, previous head of clinical development of oncology and hematology, took over Barron's position.

For more:
Roche highlights strong 2013 sales of cancer, vows to boost dividend
Post-reform Roche stumbles as top schizophrenia drug fizzles in PhIII


Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.